Danbin Xu, MD, PhD – Chief Scientific Officer


Dr. Xu serves as CellNetix’s Chief Scientific Officer where she provides strategic leadership, coordination, expertise and management of all scientific and technological innovations and research operations for the laboratory. She joined CellNetix in 2013 where she served for six years as Technical Director of Molecular Pathology and has been instrumental in the development and implementation of our clinical molecular oncology tests, including next-generation sequencing (NGS) based oncology testing for both solid tumor and hematologic malignancies.

Before joining CellNetix, Dr. Xu was Director of the molecular diagnostics laboratory at Providence Sacred Heart Medical Center in Spokane, WA, where she had designed and implemented their NGS program. She also served as Program Director and Training Director for the hospital’s ABMGG-Accredited Clinical Molecular Genetics Fellowship Program.

Dr. Xu has an M.D. from Tianjin Medical University in China and a Ph.D. in Microbiology and Molecular Genetics from Michigan State University. She completed her Clinical Molecular Genetics Fellowship at the University of Washington and is board certified by the American Board of Molecular Genetics and Genomics.

Byron Kaerstner – Senior VP of Revenue Cycle
Gregory Clark, Chief Financial Officer